News & Reports

News and Reports

Select year

2022 2021 2020 2019 2018 Earlier
shown/page
20
5 10 15 20

2021.12.01

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan

Full text

2020.06.24

Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Adult T-cell Leukemia/lymphoma in Japan

Full text

2021.04.16

Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA)
Chipscreen received a Phase 1b/2 clinical trial of Chiauranib/CS2164 IND clearance from the US Food and Drug Administration (FDA)

Full text

2021.01.11

Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the N
Pivotal phase III clinical trial IND submission of the original innovative anticancer drug Chiauranib for the treatment of small cell lung cancer was accepted by the Center of Drug Evaluation of the N

Full text

2020.12.16

Chipscreen and HISUN reach a strategic cooperation
Chipscreen and HISUN reach a strategic cooperation

Full text

2020.03.24

Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted
Chipscreen Biosciences's Original New Drug CS12192: Investigational New Drug (IND) Application Accepted

Full text

2019.12.03

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication
National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) for Breast Cancer Indication

Full text

2019.10.09

Chipscreen and Novogene enter a strategic partnership for companion diagnostics development
Chipscreen and Novogene enter a strategic partnership for companion diagnostics development

Full text

2019.09.20

Chipscreeen Biosciences’s Original New Drug Bilessglu® (for Type 2 Diabetes): Commercialization Application Accepted
Chipscreeen Biosciences’s Original New Drug Bilessglu® (for Type 2 Diabetes): Commercialization Application Accepted

Full text

2018.05.30

Good News! CHIPSCREEN BIOSCIENCES Is Approved to Be Provincial Engineering Research Center
Good News! CHIPSCREEN BIOSCIENCES Is Approved to Be Provincial Engineering Research Center

Full text

2018.05.19

The CHIPSCREEN BIOSCIENCES was invited to participate in celebration of 40th anniversary of WHO Uppsala Monitoring Center
The CHIPSCREEN BIOSCIENCES was invited to participate in celebration of 40th anniversary of WHO Uppsala Monitoring Center

Full text

2018.04.27

Asian Pharmaceutical Organization Cooperation Conference ( APAC ) and Drug Development Alliance Working Group ( DA-EWG) visits the CHIPSCREEN BIOSCIENCES
Asian Pharmaceutical Organization Cooperation Conference ( APAC ) and Drug Development Alliance Working Group ( DA-EWG) visits the CHIPSCREEN BIOSCIENCES

Full text

2018.04.25

Master core technology and make China's own innovative medicine - Dr. Lu Xianping, the chairman of CHIPSCREEN BIOSCIENCES, won " 2017 China pharmaceutical development award for outstanding achiev
Master core technology and make China's own innovative medicine - Dr. Lu Xianping, the chairman of CHIPSCREEN BIOSCIENCES, won " 2017 China pharmaceutical development award for outstanding achiev

Full text

2018.04.12

Dr. Lu was invited to attend the first global forum of 30 Chinese scientists for innovation and transformation
Dr. Lu was invited to attend the first global forum of 30 Chinese scientists for innovation and transformation

Full text

2018.01.03

Dr. Lu, the president of CHIPSCREEN BIOSCIENCES and the company, were honored with " 2017 Let Love Go Home Project"
Dr. Lu, the president of CHIPSCREEN BIOSCIENCES and the company, were honored with " 2017 Let Love Go Home Project"

Full text

2017.12.13

Innovation leads to future and patents build strength - CHIPSCREEN BIOSCIENCES wins Chinese Patent Gold Award
Innovation leads to future and patents build strength - CHIPSCREEN BIOSCIENCES wins Chinese Patent Gold Award

Full text

2017.11.23

Experts from the adverse reaction monitoring center of the state general administration visited CHIPSCREEN BIOSCIENCES for research
Experts from the adverse reaction monitoring center of the state general administration visited CHIPSCREEN BIOSCIENCES for research

Full text

2017.11.07

The third histone deacetylase inhibitor (HDACi) summit was successfully held in Nanjing
The third histone deacetylase inhibitor (HDACi) summit was successfully held in Nanjing

Full text

2017.10.20

Chengdu Microchip Pharmaceutical co., ltd. holds celebration for the commencement of innovative medicine research and development center and regional headquarters project
Chengdu Microchip Pharmaceutical co., ltd. holds celebration for the commencement of innovative medicine research and development center and regional headquarters project

Full text

2017.10.20

[ 2017 CSCA academic conference ] Experts from various fields discuss the application and latest progress of Chidamide in clinical tumor treatment.
[ 2017 CSCA academic conference ] Experts from various fields discuss the application and latest progress of Chidamide in clinical tumor treatment.

Full text
Media contact

Media contact

  • Media contact

    (+86)0755-36993500

  • Media contact

    pr@chipscreen.com